{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:18:11Z","timestamp":1775611091416,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40291-024-00766-2","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T09:47:18Z","timestamp":1736588838000},"page":"249-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multicenter In-House Evaluation of an Amplicon-Based Next\u2212Generation Sequencing Panel for Comprehensive Molecular Profiling"],"prefix":"10.1007","volume":"29","author":[{"given":"Eloisa","family":"Jantus-Lewintre","sequence":"first","affiliation":[]},{"given":"Alessandra","family":"Rappa","sequence":"additional","affiliation":[]},{"given":"Dina","family":"Ruano","sequence":"additional","affiliation":[]},{"given":"Demi","family":"van Egmond","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Gallach","sequence":"additional","affiliation":[]},{"given":"Dilce","family":"Gozuyasli","sequence":"additional","affiliation":[]},{"given":"Cec\u00edlia","family":"Dur\u00e3es","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Camps","sequence":"additional","affiliation":[]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[]},{"given":"Karl","family":"Kashofer","sequence":"additional","affiliation":[]},{"given":"Tom","family":"van Wezel","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Barberis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"issue":"5","key":"766_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744\u201350.","journal-title":"Nat Med"},{"issue":"1","key":"766_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12920-021-00952-9","volume":"14","author":"M Ozdogan","year":"2021","unstructured":"Ozdogan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou VM, Tsaousis G, et al. Comprehensive tumor molecular profile analysis in clinical practice. BMC Med Genom. 2021;14(1):105.","journal-title":"BMC Med Genom"},{"issue":"9","key":"766_CR3","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895\u2013902.","journal-title":"Ann Oncol"},{"issue":"8","key":"766_CR4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232\u201343.","journal-title":"Ann Oncol"},{"issue":"1","key":"766_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7(1): 100336.","journal-title":"ESMO Open."},{"issue":"3","key":"766_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27(3):167\u201374.","journal-title":"Oncologist"},{"issue":"9","key":"766_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","volume":"30","author":"C Marchio","year":"2019","unstructured":"Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417\u201327.","journal-title":"Ann Oncol"},{"key":"766_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157: 103194.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"766_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1369\/0022155420945050","volume":"68","author":"W Mathieson","year":"2020","unstructured":"Mathieson W, Thomas GA. Why Formalin-fixed, Paraffin-embedded biospecimens must be used in genomic medicine: an evidence-based review and conclusion. J Histochem Cytochem. 2020;68(8):543\u201352.","journal-title":"J Histochem Cytochem"},{"issue":"20","key":"766_CR10","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.3390\/cancers13205230","volume":"13","author":"LK Vestergaard","year":"2021","unstructured":"Vestergaard LK, Oliveira DNP, Poulsen TS, Hogdall CK, Hogdall EV. Oncomine comprehensive assay v3 vs. oncomine comprehensive assay plus. Cancers (Basel). 2021;13(20):5230.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"766_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/jpm13010042","volume":"13","author":"AL Ottestad","year":"2022","unstructured":"Ottestad AL, Huang M, Emdal EF, Mjelle R, Skarpeteig V, Dai HY. Assessment of two commercial comprehensive gene panels for personalized cancer treatment. J Pers Med. 2022;13(1):42.","journal-title":"J Pers Med."},{"issue":"2","key":"766_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"A Amatu","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2): e000023.","journal-title":"ESMO Open."},{"issue":"2","key":"766_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):271\u201382.","journal-title":"Lancet Oncol"},{"issue":"8","key":"766_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"766_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","volume":"32","author":"C Belli","year":"2021","unstructured":"Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021;32(3):337\u201350.","journal-title":"Ann Oncol"},{"issue":"5","key":"766_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.pathol.2023.05.002","volume":"55","author":"MA Nguyen","year":"2023","unstructured":"Nguyen MA, Colebatch AJ, Van Beek D, Tierney G, Gupta R, Cooper WA. NTRK fusions in solid tumours: what every pathologist needs to know. Pathology. 2023;55(5):596\u2013609.","journal-title":"Pathology"},{"issue":"12","key":"766_CR17","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021;32(12):1626\u201336.","journal-title":"Ann Oncol"},{"issue":"17","key":"766_CR18","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021;27(17):4680\u20134.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"766_CR19","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"766_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jmoldx.2016.07.008","volume":"19","author":"Y Wang","year":"2017","unstructured":"Wang Y, Shi C, Eisenberg R, Vnencak-Jones CL. Differences in microsatellite instability profiles between endometrioid and colorectal cancers: a potential cause for false-negative results? J Mol Diagn. 2017;19(1):57\u201364.","journal-title":"J Mol Diagn"},{"issue":"5","key":"766_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41379-018-0179-3","volume":"32","author":"X Wu","year":"2019","unstructured":"Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Mod Pathol. 2019;32(5):650\u20138.","journal-title":"Mod Pathol"},{"issue":"17","key":"766_CR22","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27(17):4685\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"766_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R Buttner","year":"2019","unstructured":"Buttner R, Longshore JW, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1): e000442.","journal-title":"ESMO Open."},{"issue":"1","key":"766_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jmoldx.2016.09.006","volume":"19","author":"S Kim","year":"2017","unstructured":"Kim S, Park C, Ji Y, Kim DG, Bae H, van Vrancken M, et al. Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine. J Mol Diagn. 2017;19(1):137\u201346.","journal-title":"J Mol Diagn"},{"issue":"6","key":"766_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41379-019-0430-6","volume":"33","author":"M Huhns","year":"2020","unstructured":"Huhns M, Nurnberg S, Kandashwamy KK, Maletzki C, Bauer P, Prall F. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Mod Pathol. 2020;33(6):1220\u201331.","journal-title":"Mod Pathol"},{"issue":"1","key":"766_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","volume":"41","author":"X Ma","year":"2022","unstructured":"Ma X, Dong L, Liu X, Ou K, Yang L. POLE\/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res. 2022;41(1):216.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"766_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373.","journal-title":"Cancer Cell"},{"issue":"9","key":"766_CR28","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-20-3991","volume":"81","author":"X Wang","year":"2021","unstructured":"Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, et al. Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Cancer Res. 2021;81(9):2566\u201373.","journal-title":"Cancer Res"},{"issue":"11","key":"766_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jmoldx.2024.08.001","volume":"26","author":"HP Adams","year":"2024","unstructured":"Adams HP, Hiemenz MC, Hertel K, Fuhlbruck F, Thomas M, Oughton J, et al. Comparison of results from two commercially available in-house tissue-based comprehensive genomic profiling solutions: research use only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay. J Mol Diagn. 2024;26(11):1018\u201333.","journal-title":"J Mol Diagn"},{"issue":"2","key":"766_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000533810","volume":"91","author":"A Mesquita","year":"2024","unstructured":"Mesquita A, Ferro A, Machado JC, Schmitt F. Next-generation sequencing of breast cancer in the neoadjuvant setting. Pathobiology. 2024;91(2):114\u201320.","journal-title":"Pathobiology"},{"issue":"1","key":"766_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14791\/btrt.2023.0036","volume":"12","author":"T Kim","year":"2024","unstructured":"Kim T, Lee A, Ahn S, Park JS, Jeun SS, Lee YS. Comprehensive molecular genetic analysis in glioma patients by next generation sequencing. Brain Tumor Res Treat. 2024;12(1):23\u201339.","journal-title":"Brain Tumor Res Treat."},{"issue":"18","key":"766_CR32","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.3390\/diagnostics13182962","volume":"13","author":"A Tsantikidi","year":"2023","unstructured":"Tsantikidi A, Papadopoulou E, Metaxa-Mariatou V, Kapetsis G, Tsaousis G, Meintani A, et al. The utility of NGS analysis in homologous recombination deficiency tracking. Diagnostics (Basel). 2023;13(18):2962.","journal-title":"Diagnostics (Basel)."}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00766-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:49:26Z","timestamp":1740466166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00766-2","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"9 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported in part by Thermo Fisher Scientific in the form of reagents. The content is solely the responsibility of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dilce Gozuyasli, Cec\u00edlia Dur\u00e3es, and Jos\u00e9 Luis Costa are employees of Thermo Fisher Scientific. Eloisa Jantus-Lewintre, Alessandra Rappa, Dina Ruano, Demi van Egmond, Sandra Gallach, Carlos Camps, Ludovic Lacroix, Karl Kashofer, Tom van Wezel, and Massimo Barberis have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was based on pre-existing biological materials and data, which were reanalyzed using a new method. All procedures were conducted in accordance with the ethical standards outlined by the relevant institutional and\/or national research committees and adhered to the principles of the Helsinki Declaration (revised in 2013). The study received approval from the following ethics committees: Medical University of Graz (33-112 ex 20\/21), Istituto Europeo di Oncologia (IEO DSC.MO.7720), Leiden University Medical Center (following the Code Proper Secondary Use of Human Tissue established by the Dutch Federation of Medical Sciences, ), Institut Gustave Roussy (s\/n), Fundaci\u00f3n Investigaci\u00f3n Hospital General Universitario (s\/n).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients to use their biological samples for research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MB and JLC designed the study; EJ-L, CC, LL, KK, and TvW performed the data interpretation; AR, DR, DvE, and SG performed the experiments and data analysis; DG and CD performed the data analysis and visualization; EJL, CC, LL, KK, TvW, MB, DR, and DG revised the manuscript; CD and JLC reviewed and edited the manuscript. All authors have read and agreed to the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}